Moss E, Burrell A, Lee J, Reichenbach D, Mitchell S, Yan S, Thiruvillakkat K. Economic and humanistic burden in kidney transplant rejection: a literature review. Expert Rev Pharmacoecon Outcomes Res. 2024 Mar;24(3):343-52. doi: 10.1080/14737167.2024.2305140
Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Fliser D, Lorenzo MM, Houghton K, Ainsworth C, Blogg M, Gonzalez de Antona Sanchez E, Portles J. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-29. doi: 10.2147/IJNRD.S401598
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment structures and resource use in non-dialysis-dependent CKD patients (NDD-CKD) with renal anemia: a retrospective analysis. Poster presented at the Kongress fur NepHROlogie 2021 13th Annual Meeting; September 23, 2021.
Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment of anaemia with erythropoiesis-stimulating agents (ESAs) and concomitant therapies among patients with non-dialysis dependent chronic kidney disease (NDD-CKD) in Germany, Spain and the UK: a retrospective chart review. Poster presented at the 2021 58th ERA-EDTA Virtual Congress; June 5, 2021.
Mader G, Mladsi (she/her) D, Zhou X, Sanon M, Wang J, Willey C, Seliger S. Racial differences in mortality rates among elderly Non-ESRD CKD and ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the USRDS. Poster presented at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings; April 2021.
Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.
DaCosta Byfield S, McPheeters JT, Burton T, Nagar SP, Hackshaw MD. Persistence and compliance among US patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma. J Manag Care Pharm. 2015 Jun;21(6):515-22.
Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Pharm. 2015 Jan;21(1):37-44.
Davis AE, Mehrotra S, Kilambi V, Kang J, McElroy L, Lapin B, Holl J, Abecassis M, Friedewald JJ, Ladner DP. The effects of the statewide sharing variance on geographic disparity in kidney transplantation in the United States. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1149-60.
Hackshaw MD, Nagar SP, Parks DC, Miller LA. Persistence and compliance with Pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database. J Manag Care Pharm. 2014 Jun;20(6):603-10.
Copley-Merriman K, Olanrewaju B, Hogue S. The temporal relationship between NSAIDS and risk of gastrointestinal, cardiovascular, and renal events: a systematic review. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2, 2013. [abstract] Value Health. 2013 May; 16(3):A110.
Ferguson JE3rd, Goyal RK, Raynor MC, Nielsen ME, Pruthi RS, Brown PM, Wallen EM. Cost analysis of robot-assisted laparoscopic versus hand-assisted laparoscopic partial nephrectomy. J Endourol. 2012 Aug;26(8):1030-7.
Lang K, Meyers JL, Kovacs B, Candrilli SD. Renal impairment in patients with type 2 diabetes mellitus and associated antihyperglycemic medication adjustment: evidence from an electronic medical records database. Poster presented at the 43rd Annual Meeting and Scientific Exposition of the American Society of Nephrology; November 2010.
Davis AE, Ladner D, Friedewald J. Analysis of dialysis center locations in Illinois. Poster presented at the American Transplant Congress; May 2010.
Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.
Bernardo M, Globe D, Kewalramani R, Masaquel CJ. Costs of anemia management in chronic disease (CKD) from the perspective of the payor, patient, and family. Poster presented at the American Society of Nephrology; November 2006.
Bell T, Candrilli S, Irish W, Morris E, Cairo MS. Medical resource use and costs associated with renal complications among patients with hematologic malignancies. Blood. 2002 Jan 1;100(11):221A.